HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia.

AbstractBACKGROUND:
Current recommendations for prophylaxis of Pneumocystis carinii pneumonia (PCP) are based on data from patients who have had at least one episode of PCP (secondary prevention). We designed a study to determine the efficacy and side effects of inhaled pentamidine in the primary prevention of PCP.
METHODS:
Two hundred twenty-three patients sero-positive for human immunodeficiency virus (HIV) who had the acquired immunodeficiency syndrome (AIDS) but not PCP, who had advanced AIDS-related complex, or who had less than 0.2 x 10(9) CD4-positive lymphocytes per liter received either 300 mg of pentamidine isethionate or 300 mg of sodium isethionate every 28 days by inhaler. The proportion of patients surviving without PCP was analyzed with the log-rank test as a function of time spent in the trial, according to the intention to treat with either placebo or pentamidine.
RESULTS:
The third of five planned interim analyses showed a significant difference in the occurrence of PCP, with 8 cases in pentamidine group and 23 in the placebo group (nominal P value = 0.0021). There were no deaths within 60 days of the diagnosis of PCP and no significant differences in survival between groups. Approximately 53 inhalations were needed to prevent one episode of pneumonia. Thirty-eight of 114 patients given pentamidine (33 percent) and 7 of 109 given placebo (6 percent) had moderate-to-severe coughing during inhalations (two-tailed P less than 0.00001), which caused 4 patients given pentamidine (3.5 percent) to discontinue taking it.
CONCLUSIONS:
A dose of 300 mg of aerosolized pentamidine given every four weeks was well tolerated and 60 to 70 percent effective in preventing a first episode of PCP in patients with HIV infection.
AuthorsB Hirschel, A Lazzarin, P Chopard, M Opravil, H J Furrer, S Rüttimann, P Vernazza, J P Chave, F Ancarani, V Gabriel
JournalThe New England journal of medicine (N Engl J Med) Vol. 324 Issue 16 Pg. 1079-83 (Apr 18 1991) ISSN: 0028-4793 [Print] United States
PMID2008181 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Aerosols
  • Pentamidine
Topics
  • AIDS-Related Complex (complications)
  • Acquired Immunodeficiency Syndrome (complications)
  • Administration, Inhalation
  • Adolescent
  • Adult
  • Aerosols
  • Aged
  • Female
  • HIV Seropositivity (complications)
  • Humans
  • Male
  • Middle Aged
  • Pentamidine (administration & dosage, adverse effects, therapeutic use)
  • Pneumonia, Pneumocystis (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: